Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Ibrutinib in R/R MCL (AIM)
NCT02471391Phase 2Unknown
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jul 2015
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in mantle cell lymphoma (MCL), sponsored by Peter MacCallum Cancer Centre. Status: unknown.
02
Drugs
venetoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02471391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02471391.